Jerome Goldstein, M.D. is a Board-certified medical neurologist who has a special interest in the diagnosis, treatment, prevention, and cure of headache. Dr. Goldstein is also a member of The American Headache Society, The International Headache Society, and The National Headache Foundation.
Dr. Goldstein was recently named President of the Headache and Facial Pain Section of the American Academy of Neurology. He will be providing periodic updates on the San Francisco Headache Clinic Website about the activities of the AAN's Headache and Facial Pain Section as well as the American Association for the Study of Headache and the National Headache Foundation.
Dr. Goldstein graduated from the Upstate Medical Center in Syracuse, New York and completed his Neurology residency at the University of California in San Francisco in 1970. He is certified by the American Board of Psychiatry and Neurology and is the Director of the San Francisco Clinical Research Center, the San Francisco Headache Clinic and the San Francisco Alzheimer's and Dementia Clinic.
He is an Assistant Clinical Professor of Neurology at the University of California in San Francisco and is an active member of several organizations including the American Headache Society (AASH), the National Headache Foundation (NHF) and the International Headache Society (IHS).
In addition, Dr. Goldstein is a Fellow member of the American Association for the Study of Headache and the American Academy of Neurology (AAN). He is the President of the AAN's Headache and Facial Pain Section and Newsletter Editor-in-Chief. He is an active member of the American Academy of Neurology's Section's Committee for Practice Standards and Director of its Annual Course, "Case Studies in Headache".
Dr. Goldstein has directed research studies on every new 5-HT 1D receptor agonists, including the original pilot studies done on Imitrex® in the United States and has conducted clinical trials on all new prophylactic agents in headache.
Dr. Goldstein has authored many research publications in the field of headache. He is a pioneer on multimedia scientific and educational presentations on pain and headache, especially the general nature of headache, the comparison of the 5-HT 1D receptor agonists, the role of opiates in pain and headache management, caffeine in headache medications and new triptans. Dr. Goldstein is currently pursuing new research dealing with the meta-analysis of triptans.
Recently, Dr. Goldstein has been honored by giving multimedia presentations at the International Headache Society in Barcelona, Spain; the Brazilian Headache Society in Brazil; the German Pain Congress in Dusseldorf, Germany; the European Federation of Neurological Societies in Seville, Spain; the XII Migraine International Symposium in London, England; and the 4th Congress of European Headache Federation in Corfu, Greece.
At the International Headache Society meeting in Armsterdam, Holland, Dr. Goldstein was honored with the opportunity to give a special salute presentation for those who have contributed instrumentally to the advancement in the understanding of headaches.
